Paclitaxel is one of the most effective and well tolerated anti-cancer drugs used for advanced metastatic breast����cancer treatment. We treated a 70-year-old woman with metastatic breast cancer who had developed Stevens-Johnsonsyndrome after intravenous administration of the first dose of paclitaxel. Stevens-Johnson syndrome is a rare, severe,immune-mediated cutaneous reaction to medication. Drug lymphocyte stimulation test���� was performed and Paclitaxel waslikely to be a cause of this complication . The patient was treated with steroid pulse therapy with intravenousimmunoglobulin. This case report serves as an alert for the need to observe patients carefully for potentially severe cutaneousreactions to paclitaxel.
再発乳癌患者に対しパクリタキセルを投与した際に発症したStevens-Johnson症候群の一例
jsums2401p031.pdf
(3.17MB)
